

Applicants : Graham P. Allaway
Serial No. : Not Yet Known
Filed : December 13, 1999
Page 2

HIV-1 infection of the CD4+ cells, provided that the nonchemokine peptidyl agent is not a bicyclam or a derivative thereof.

B
B
A2
~~62.~~ (New) The method of claim 61, wherein the non-chemokine peptidyl agent is an oligopeptide.

A2
~~63.~~ (New) The method of claim 61, wherein the non-chemokine peptidyl agent is a polypeptide.

B
~~64.~~ (New) The method of claim 63, wherein the non-chemokine peptidyl agent is an antibody or portion of an antibody.

Remarks:


Claims 1-60 were pending in the subject application. Applicants have hereinabove canceled claims 1-60 without prejudice to their right to pursue the subject matter of these claims in a later-filed application and added new claims 61-64 as follows. Support for these amendments may be found inter alia in the specification as follows: claim 61: page 13, lines 1-6, page 14, lines 6-10 and 21-22; claim 62: page 14, lines 13-14; claim 63, lines 14-15; claim 64, lines 15-17. Accordingly, claims 61-64 involve no issue of new matter and entry of this amendment is respectfully requested.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

Applicants : Graham P. Allaway
Serial No. : Not Yet Known
Filed : December 13, 1999
Page 3

No fee, in addition to the enclosed filing fee of \$380.00, is deemed necessary in connection with the filing of this Preliminary Amendment. However, if any additional fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,


John P. White
Registration No. 28,678
Attorney for Applicant(s)
Cooper & Dunham, LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400